Correction to: Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort
Cancer Immunol Immunother. 2020 Jul;69(7):1189.
doi: 10.1007/s00262-020-02582-z.
1 Division of Cancer Treatment and Diagnosis, Developmental Therapeutics Clinic, National Cancer Institute, Bldg 31/3A44, 31 Centre Drive, Bethesda, MD, 20892, USA. abdulrafeh.naqash@nih.gov.
2 Division of Hematology/Oncology, Department of Internal Medicine, East Carolina University, Greenville, NC, USA. abdulrafeh.naqash@nih.gov.
3 Thoracic Oncology Unit, Santa Maria Della Misericordia Hospital, University of Perugia, Perugia, Italy.
4 Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
5 Division of Medical Oncology, Department of Internal Medicine, Ohio State University, Columbus, OH, USA.
6 Division of Oncology, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA.
7 Division of Medical Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
8 Department of Pulmonary Medicine, Sendai Kousei Hospital, Hirosemachi, Aoba-Ku, Sendai, Japan.
9 Division of Cancer Treatment and Diagnosis, Developmental Therapeutics Clinic, National Cancer Institute, Bldg 31/3A44, 31 Centre Drive, Bethesda, MD, 20892, USA.
10 Division of Hematology/Oncology, Department of Internal Medicine, East Carolina University, Greenville, NC, USA.
11 Department of Pulmonary Medicine, East Carolina University, Greenville, NC, USA.
12 Memorial Sloan Kettering Cancer Center, New York, USA.